Compare IOL Chemicals with Similar Stocks
Dashboard
The company is Net-Debt Free
Poor long term growth as Net Sales has grown by an annual rate of 0.38% and Operating profit at 7.22% over the last 5 years
Positive results in Dec 25
With ROE of 6.6, it has a Very Expensive valuation with a 1.8 Price to Book Value
Rising Promoter Confidence
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
INR 2,979 Cr (Small Cap)
26.00
44
1.03%
-0.01
6.62%
1.63
Total Returns (Price + Dividend) 
Latest dividend: 1 per share ex-dividend date: Feb-17-2026
Risk Adjusted Returns v/s 
Returns Beta
News

IOL Chemicals & Pharmaceuticals Ltd Surges 7.07% to Day's High of Rs 104.4 — Outperforms Sector by 7.13 Percentage Points
While the Sensex declined by 1.16% on 11 May 2026, IOL Chemicals & Pharmaceuticals Ltd surged 7.07%, reaching an intraday high of Rs 104.4. This 7.13 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers highlights a distinctly stock-specific rally amid a broadly weak market environment.
Read full news article
IOL Chemicals & Pharmaceuticals Ltd: Valuation Shifts Signal Price Attractiveness Challenges
IOL Chemicals & Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from an expensive to a very expensive rating, despite delivering robust returns over recent periods. This recalibration in price attractiveness, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, invites a closer examination of the stock’s current standing relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector.
Read full news article
IOL Chemicals & Pharmaceuticals Ltd is Rated Hold
IOL Chemicals & Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 28 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Read full news article Announcements 
Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015
09-May-2026 | Source : BSEDisclosure under regulation 39 of Sexurities and Exchange Board of India(Listing Obligations and Disclosure Requirements) Regulations2015
Announcement under Regulation 30 (LODR)-Newspaper Publication
10-Apr-2026 | Source : BSESubmission of Newspaper publication
Disclosure Under Regulation 30 - Participation In Saksham Niveshak Campaign
09-Apr-2026 | Source : BSEDisclosure under Regulation 30
Corporate Actions 
No Upcoming Board Meetings
IOL Chemicals & Pharmaceuticals Ltd has declared 50% dividend, ex-date: 17 Feb 26
IOL Chemicals & Pharmaceuticals Ltd has announced 2:10 stock split, ex-date: 11 Mar 25
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 6 Schemes (0.02%)
Held by 53 FIIs (1.72%)
Maya Devi Polycot Limited (21.79%)
Synthorix Trading Limited (3.81%)
31.03%
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
QoQ Growth in quarter ended Dec 2025 is 2.27% vs 2.87% in Sep 2025
QoQ Growth in quarter ended Dec 2025 is -31.33% vs -11.67% in Sep 2025
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 8.86% vs -7.25% in Sep 2024
Growth in half year ended Sep 2025 is 30.09% vs -41.34% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 9.55% vs -4.75% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 21.29% vs -34.79% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is -2.51% vs -3.80% in Mar 2024
YoY Growth in year ended Mar 2025 is -24.82% vs -3.39% in Mar 2024






